1. Charlson FJ, Ferrari AJ, Santomauro DF, Diminic S, Stockings E, Scott JG, McGrath JJ, Whiteford HA: Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016. Schizophrenia bulletin 2018, 44(6):1195-1203.
2. Stepnicki P, Kondej M, Kaczor AA: Current Concepts and Treatments of Schizophrenia. Molecules 2018, 23(8).
3. Jena M, Ranjan R, Mishra BR, Mishra A, Nath S, Sahu P, Meher BR, Srinivasan A, Maiti R: Effect of lurasidone vs olanzapine on neurotrophic biomarkers in unmedicated schizophrenia: A randomized controlled trial. J Psychiatr Res 2019, 112:1-6.
4. Ruiz de Azua S, Matute C, Stertz L, Mosquera F, Palomino A, de la Rosa I, Barbeito S, Vega P, Kapczinski F, González-Pinto A: Plasma brain-derived neurotrophic factor levels, learning capacity and cognition in patients with first episode psychosis. BMC psychiatry 2013, 13:27.
5. Agim ZS, Esendal M, Briollais L, Uyan O, Meschian M, Martinez LA, Ding Y, Basak AN, Ozcelik H: Discovery, validation and characterization of Erbb4 and Nrg1 haplotypes using data from three genome-wide association studies of schizophrenia. PLoS One 2013, 8(1):e53042.
6. Fornasari BE, El Soury M, De Marchis S, Perroteau I, Geuna S, Gambarotta G: Neuregulin1 alpha activates migration of neuronal progenitors expressing ErbB4. Mol Cell Neurosci 2016, 77:87-94.
7. Mei L, Xiong WC: Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci 2008, 9(6):437-452.
8. Buonanno A: The neuregulin signaling pathway and schizophrenia: from genes to synapses and neural circuits. Brain Res Bull 2010, 83(3-4):122-131.
9. Lewis DA, Gonzalez-Burgos G: Pathophysiologically based treatment interventions in schizophrenia. Nat Med 2006, 12(9):1016-1022.
10. Chesworth R, Rosa-Porto R, Yao S, Karl T: Sex-specific sensitivity to methamphetamine-induced schizophrenia-relevant behaviours in neuregulin 1 type III overexpressing mice. J Psychopharmacol 2021, 35(1):50-64.
11. Pan B, Huang XF, Deng C: Antipsychotic treatment and neuregulin 1-ErbB4 signalling in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35(4):924-930.
12. Law AJ, Lipska BK, Weickert CS, Hyde TM, Straub RE, Hashimoto R, Harrison PJ, Kleinman JE, Weinberger DR: Neuregulin 1 transcripts are differentially expressed in schizophrenia and regulated by 5' SNPs associated with the disease. Proceedings of the National Academy of Sciences of the United States of America 2006, 103(17):6747-6752.
13. Parlapani E, Schmitt A, Wirths O, Bauer M, Sommer C, Rueb U, Skowronek MH, Treutlein J, Petroianu GA, Rietschel M et al: Gene expression of neuregulin-1 isoforms in different brain regions of elderly schizophrenia patients. World J Biol Psychiatry 2010, 11(2 Pt 2):243-250.
14. Mata I, Perez-Iglesias R, Roiz-Santianez R, Tordesillas-Gutierrez D, Gonzalez-Mandly A, Vazquez-Barquero JL, Crespo-Facorro B: A neuregulin 1 variant is associated with increased lateral ventricle volume in patients with first-episode schizophrenia. Biol Psychiatry 2009, 65(6):535-540.
15. Gruber O, Falkai P, Schneider-Axmann T, Schwab SG, Wagner M, Maier W: Neuregulin-1 haplotype HAP(ICE) is associated with lower hippocampal volumes in schizophrenic patients and in non-affected family members. J Psychiatr Res 2008, 43(1):1-6.
16. Zhang HX, Zhao JP, Lv LX, Li WQ, Xu L, Ouyang X, Yuan ZQ, Huang JS: Explorative study on the expression of neuregulin-1 gene in peripheral blood of schizophrenia. Neurosci Lett 2008, 438(1):1-5.
17. Mostaid MS, Lee TT, Chana G, Sundram S, Shannon Weickert C, Pantelis C, Everall I, Bousman C: Elevated peripheral expression of neuregulin-1 (NRG1) mRNA isoforms in clozapine-treated schizophrenia patients. Transl Psychiatry 2017, 7(12):1280.
18. Kastin AJ, Akerstrom V, Pan W: Neuregulin-1-beta1 enters brain and spinal cord by receptor-mediated transport. J Neurochem 2004, 88(4):965-970.
19. Leucht S, Davis JM, Engel RR, Kane JM, Wagenpfeil S: Defining 'response' in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs. Neuropsychopharmacology 2007, 32(9):1903-1910.
20. Faul F, Erdfelder E, Lang AG, Buchner A: G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behavior research methods 2007, 39(2):175-191.
21. Wang R, Wang Y, Hu R, Chen X, Song M, Wang X: Decreased plasma levels of neureglin-1 in drug naive patients and chronic patients with schizophrenia. Neurosci Lett 2015, 606:220-224.
22. Zhang Z, Cui J, Gao F, Li Y, Zhang G, Liu M, Yan R, Shen Y, Li R: Elevated cleavage of neuregulin-1 by beta-secretase 1 in plasma of schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry 2019, 90:161-168.
23. Yamamori H, Hashimoto R, Verrall L, Yasuda Y, Ohi K, Fukumoto M, Umeda-Yano S, Ito A, Takeda M: Dysbindin-1 and NRG-1 gene expression in immortalized lymphocytes from patients with schizophrenia. J Hum Genet 2011, 56(7):478-483.
24. Bertram I, Bernstein HG, Lendeckel U, Bukowska A, Dobrowolny H, Keilhoff G, Kanakis D, Mawrin C, Bielau H, Falkai P et al: Immunohistochemical evidence for impaired neuregulin-1 signaling in the prefrontal cortex in schizophrenia and in unipolar depression. Ann N Y Acad Sci 2007, 1096:147-156.
25. Hashimoto R, Straub RE, Weickert CS, Hyde TM, Kleinman JE, Weinberger DR: Expression analysis of neuregulin-1 in the dorsolateral prefrontal cortex in schizophrenia. Mol Psychiatry 2004, 9(3):299-307.
26. Dang R, Guo Y, Cai H, Yang R, Liang D, Lv C, Jiang P: Effects of prolonged antipsychotic administration on neuregulin-1/ErbB signaling in rat prefrontal cortex and myocardium: implications for the therapeutic action and cardiac adverse effect. The Journal of toxicological sciences 2016, 41(2):303-309.
27. Hahn CG, Wang HY, Cho DS, Talbot K, Gur RE, Berrettini WH, Bakshi K, Kamins J, Borgmann-Winter KE, Siegel SJ et al: Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat Med 2006, 12(7):824-828.
28. Woo RS, Li XM, Tao Y, Carpenter-Hyland E, Huang YZ, Weber J, Neiswender H, Dong XP, Wu J, Gassmann M et al: Neuregulin-1 enhances depolarization-induced GABA release. Neuron 2007, 54(4):599-610.
29. Shibuya M, Komi E, Wang R, Kato T, Watanabe Y, Sakai M, Ozaki M, Someya T, Nawa H: Measurement and comparison of serum neuregulin 1 immunoreactivity in control subjects and patients with schizophrenia: an influence of its genetic polymorphism. J Neural Transm (Vienna) 2010, 117(7):887-895.
30. Chana G, Lucero G, Salaria S, Lozach J, Du P, Woelk C, Everall I: Upregulation of NRG-1 and VAMP-1 in human brain aggregates exposed to clozapine. Schizophr Res 2009, 113(2-3):273-276.
31. Murru A, Carpiniello B: Duration of untreated illness as a key to early intervention in schizophrenia: A review. Neurosci Lett 2018, 669:59-67.
32. Kataria H, Alizadeh A, Karimi-Abdolrezaee S: Neuregulin-1/ErbB network: An emerging modulator of nervous system injury and repair. Prog Neurobiol 2019, 180:101643.